Procurement Summary
Country : USA
Summary : Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Deadline : 07 May 2023
Other Information
Notice Type : Tender
TOT Ref.No.: 41225809
Document Ref. No. : PAR-20-111
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Purchaser : NATIONAL INSTITUTES OF HEALTH
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
USA
Email :FBOWebmaster@OD.NIH.GOV
Tender Details
Tender are invited for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
CFDA Number : 93.121 -- Oral Diseases and Disorders Research93.213 -- Research and Training in Complementary and Integrative Health93.242 -- Mental Health Research Grants93.273 -- Alcohol Research Programs93.279 -- Drug Abuse and Addiction Research Programs93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders93.865 -- Child Health and Human Development Extramural Research93.866 -- Aging Research93.867 -- Vision Research
Cost Sharing or Matching Requirement : No
Closing Date for Applications: May 07, 2023
Posted Date : Mar 03, 2020
Description: Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Documents
Tender Notice